China Advances Cancer Fight with CSPC Pharma's mRNA Therapy Trials Approval

CSPC Pharmaceutical Group (1093.HK) has announced regulatory approval in China for a new human clinical trial of its cancer cell therapy utilizing synthetic messenger RNA (mRNA) technology. This development follows the Chinese drugmaker's earlier research into mRNA for COVID-19 vaccines, prompting further exploration into applications such as cancer treatment alongside several other Chinese pharmaceutical companies.

CSPC said, “The clinical trial approval obtained for the product marks the first significant achievement of the Group in the field of cell therapy”, clicking on a fresh tab within a stock exchange filing unveils the endorsement from the China National Medical Products Administration. A CSPC spokesperson declined to provide immediate answers to Reuters inquiries regarding the technology employed in SYS6020, touted as the "world’s first mRNA-LNP-based cell therapy product approved for clinical trials.”